Tag : Antibody

Gastroenterology

P069 ONTAMALIMAB, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1, PROVIDES SUSTAINED EXPOSURE FOLLOWING LONG-TERM TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

Newsemia
Ontamalimab is a fully human immunoglobulin G2 monoclonal antibody against mucosal addressin cell adhesion molecule-1 in development for the induction and maintenance of clinical remission...
Latest News

Scientists create world’s first model of pituitary disease using human iPS cells

Newsemia
Researchers at Kobe University’s Graduate School of Medicine have developed the world’s first congenital pituitary hypoplasia model using patient-derived iPS cells. Source link...
Latest News

Universal 'One-Size-Fits-All' Cancer Treatment

Newsemia
Andrew Sewell speaks to News-Medical about his breakthrough research, in which he has discovered a new T-Cell that could treat most cancers. Source link...
Biology

Absolute Antibody Launches VivopureXâ„¢ Recombinant Antibodies for In Vivo Research

Newsemia
REDCAR, United Kingdom (PRWEB) January 07, 2020 Absolute Antibody Ltd. , an industry-leading provider of recombinant antibody products and services, today announced the launch of...
Latest News

New antibody-drug conjugate shows promising activity in salivary gland tumors

Newsemia
The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors, according to data published in the Annals of Oncology. Source...
Pharma / Biotech

Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study.

Newsemia
Related Articles Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy